Tapewire

Nasdaq · USD

CRBU

Caribou Biosciences, Inc.

Export transactions ↓
Tapewire entity
6445
SEC CIK
0001619856
Parsed reports
121

Last 12 months

Inside the activity.

0 purchase rows · 5 sale rows

Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.
Monthly counts
MonthPurchasesSales
Nov 202500
Dec 202500
Jan 202600
Feb 202605
Mar 202600
Apr 202600
May 202600
Jun 202600
Jul 202600
Aug 202600
Sep 202600
Oct 202600

Latest available

Insider transactions

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateOwner / reported roleActivity / securityShares / unitsReported priceReported valueDetails
February 25, 2026 Filed Feb 27, 2026 21:01 UTC
Kelly Timothy PChief Technology Officer
SaleCommon Stock 6,228 $1.93 $12,020.04
Disclosure

SEC source: 0001754067-26-000004 · wk-form4_1772226070.xml · nonDerivative · entry 1

Kelly Timothy P · CIK 0001754067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 73,125

Read SEC document
February 24, 2026 Filed Feb 24, 2026 20:53 UTC
Albertson Tina M.Chief Medical Officer
SaleCommon Stock 1,066 $1.96 $2,089.36
Disclosure

SEC source: 0001917391-26-000002 · wk-form4_1771984424.xml · nonDerivative · entry 2

Albertson Tina M. · CIK 0001917391 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 68,523

F2 · kind: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted by the reporting person on August 12, 2024. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F2 · shares: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted by the reporting person on August 12, 2024. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

Read SEC document
February 24, 2026 Filed Feb 24, 2026 20:54 UTC
MCCLUNG BARBARA GChief Legal Officer
SaleCommon Stock 6,938 $1.96 $13,598.48
Disclosure

SEC source: 0001231321-26-000002 · wk-form4_1771984473.xml · nonDerivative · entry 2

MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 481,564

F2 · kind: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F2 · shares: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

Read SEC document
February 24, 2026 Filed Feb 25, 2026 01:54 UTC
Kelly Timothy PChief Technology Officer
SaleCommon Stock 3,147 $1.96 $6,168.12
Disclosure

SEC source: 0001754067-26-000002 · wk-form4_1771984478.xml · nonDerivative · entry 2

Kelly Timothy P · CIK 0001754067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,353

F2 · kind: Reflects the number of shares of common stock that were sold pursuant to the Issuer's mandatory sell-to-cover policy for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person.

F2 · shares: Reflects the number of shares of common stock that were sold pursuant to the Issuer's mandatory sell-to-cover policy for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person.

Read SEC document
February 24, 2026 Filed Feb 25, 2026 01:54 UTC
Khan Ruhi AhmadChief Business Officer
SaleCommon Stock 6,938 $1.96 $13,598.48
Disclosure

SEC source: 0001891113-26-000002 · wk-form4_1771984441.xml · nonDerivative · entry 2

Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 104,998

F2 · kind: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F2 · shares: Reflects the number of shares of common stock that were sold in a "sell-to-cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 17:28 UTC GrantOption to purchase Common Stock · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001683811-26-000002 · wk-form4_1771626484.xml · derivative · entry 1

Sacks Natalie · CIK 0001683811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 17:28 UTC
Zheng RanDirector
GrantOption to purchase Common Stock · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001885914-26-000002 · wk-form4_1771626495.xml · derivative · entry 1

Zheng Ran · CIK 0001885914 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 17:26 UTC
Haurwitz Rachel E.Director · President and CEO
GrantOption to purchase Common Stock · Derivative 682,500 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001670579-26-000002 · wk-form4_1771626383.xml · derivative · entry 3

Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 682,500

Underlying: Common Stock · 682,500 shares

Expires 2036-02-19

F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 17:26 UTC
Haurwitz Rachel E.Director · President and CEO
GrantCommon Stock 151,700 $0.00 $0.00
Disclosure

SEC source: 0001670579-26-000002 · wk-form4_1771626383.xml · nonDerivative · entry 1

Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 447,150

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:27 UTC GrantOption to purchase Common Stock · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001643875-26-000004 · wk-form4_1771626422.xml · derivative · entry 1

Braunstein Scott · CIK 0001643875 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:27 UTC GrantOption to purchase Common Stock · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001230724-26-000004 · wk-form4_1771626452.xml · derivative · entry 1

GUGGENHIME ANDREW · CIK 0001230724 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:28 UTC GrantOption to purchase Common Stock · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001880609-26-000002 · wk-form4_1771626490.xml · derivative · entry 1

Whiting Nancy · CIK 0001880609 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:27 UTC GrantOption to purchase Common Stock · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001893193-26-000003 · wk-form4_1771626471.xml · derivative · entry 1

Richardson-Heron Dara · CIK 0001893193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:27 UTC GrantOption to purchase Common Stock · Derivative 45,000 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001733883-26-000004 · wk-form4_1771626459.xml · derivative · entry 1

JOHNSON DAVID LEE · CIK 0001733883 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,000

Underlying: Common Stock · 45,000 shares

Expires 2036-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:26 UTC
Ryali SriramChief Financial Officer
GrantOption to purchase Common Stock · Derivative 247,500 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001762893-26-000002 · wk-form4_1771626395.xml · derivative · entry 2

Ryali Sriram · CIK 0001762893 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 247,500

Underlying: Common Stock · 247,500 shares

Expires 2036-02-19

F2 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 20, 2026 22:26 UTC
Ryali SriramChief Financial Officer
GrantCommon Stock 55,000 $0.00 $0.00
Disclosure

SEC source: 0001762893-26-000002 · wk-form4_1771626395.xml · nonDerivative · entry 1

Ryali Sriram · CIK 0001762893 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 72,360

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 20:53 UTC
Albertson Tina M.Chief Medical Officer
GrantOption to purchase Common Stock · Derivative 247,500 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001917391-26-000002 · wk-form4_1771984424.xml · derivative · entry 3

Albertson Tina M. · CIK 0001917391 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 247,500

Underlying: Common Stock · 247,500 shares

Expires 2036-02-19

F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 20:53 UTC
Albertson Tina M.Chief Medical Officer
GrantCommon Stock 55,000 $0.00 $0.00
Disclosure

SEC source: 0001917391-26-000002 · wk-form4_1771984424.xml · nonDerivative · entry 1

Albertson Tina M. · CIK 0001917391 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 69,589

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 20:54 UTC
MCCLUNG BARBARA GChief Legal Officer
GrantOption to purchase Common Stock · Derivative 202,500 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001231321-26-000002 · wk-form4_1771984473.xml · derivative · entry 3

MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,500

Underlying: Common Stock · 202,500 shares

Expires 2036-02-19

F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 20:54 UTC
MCCLUNG BARBARA GChief Legal Officer
GrantCommon Stock 45,000 $0.00 $0.00
Disclosure

SEC source: 0001231321-26-000002 · wk-form4_1771984473.xml · nonDerivative · entry 1

MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 488,502

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:54 UTC
Kelly Timothy PChief Technology Officer
GrantOption to purchase Common Stock · Derivative 202,500 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001754067-26-000002 · wk-form4_1771984478.xml · derivative · entry 3

Kelly Timothy P · CIK 0001754067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,500

Underlying: Common Stock · 202,500 shares

Expires 2036-02-19

F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:54 UTC
Kelly Timothy PChief Technology Officer
GrantCommon Stock 45,000 $0.00 $0.00
Disclosure

SEC source: 0001754067-26-000002 · wk-form4_1771984478.xml · nonDerivative · entry 1

Kelly Timothy P · CIK 0001754067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 82,500

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:54 UTC
Khan Ruhi AhmadChief Business Officer
GrantOption to purchase Common Stock · Derivative 202,500 $0.00 Strike: $1.80 $0.00
Disclosure

SEC source: 0001891113-26-000002 · wk-form4_1771984441.xml · derivative · entry 3

Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 202,500

Underlying: Common Stock · 202,500 shares

Expires 2036-02-19

F3 · derivative.exercise_date: 1/48 of the total number of shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2030, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2026 Filed Feb 25, 2026 01:54 UTC
Khan Ruhi AhmadChief Business Officer
GrantCommon Stock 45,000 $0.00 $0.00
Disclosure

SEC source: 0001891113-26-000002 · wk-form4_1771984441.xml · nonDerivative · entry 1

Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,936

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2027, subject to the reporting person continuing to provide service to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
March 14, 2025 Filed Mar 17, 2025 08:01 UTC
Haurwitz Rachel E.Director · President and CEO
PurchaseCommon Stock 20,000 $1.02 $20,400.00
Disclosure

SEC source: 0001670579-25-000008 · wk-form4_1742212876.xml · nonDerivative · entry 2

Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 3,369,395

F1 · price: This transaction was executed in multiple trades on 3/14/2025 at prices ranging from $1.00 to $1.03 per share, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price within the specified range.

F2 · ownership.nature: Shares are held by The City Canyon Family Trust dated May 31, 2021, of which the Reporting Person is a Co-Trustee with her spouse.

Read SEC document
February 21, 2025 Filed Feb 21, 2025 20:19 UTC
MCCLUNG BARBARA GChief Legal Officer
SaleCommon Stock 3,564 $1.35 $4,811.40
Disclosure

SEC source: 0001231321-25-000003 · wk-form4_1740187189.xml · nonDerivative · entry 2

MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 443,502

F2 · kind: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F2 · shares: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F3 · price: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range.

Read SEC document
February 21, 2025 Filed Feb 22, 2025 01:19 UTC
Khan Ruhi AhmadChief Business Officer
SaleCommon Stock 3,564 $1.35 $4,811.40
Disclosure

SEC source: 0001891113-25-000003 · wk-form4_1740187160.xml · nonDerivative · entry 2

Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,936

F2 · kind: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F2 · shares: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F3 · price: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range.

Read SEC document
February 21, 2025 Filed Feb 22, 2025 01:18 UTC
Kanner StevenChief Scientific Officer
SaleCommon Stock 3,564 $1.35 $4,811.40
Disclosure

SEC source: 0001871131-25-000003 · wk-form4_1740187088.xml · nonDerivative · entry 2

Kanner Steven · CIK 0001871131 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 431,556

F3 · kind: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F3 · shares: Reflects the number of shares of common stock that were sold in a "sell to cover" transaction for the sole purpose of satisfying tax withholding obligations in connection with the vesting of RSUs previously granted to the reporting person and does not represent a discretionary trade by the reporting person. This transaction was made pursuant to a Rule 10b5-1 trading plan in the form of a durable sell-to-cover instruction adopted prior to the 2023 amendments to Rule 10b5-1. The trading plan provides for the automatic sale of shares of common stock necessary to satisfy the reporting person's tax withholding obligations incurred in connection with the vesting of RSUs.

F4 · price: This transaction was executed in multiple trades on 2/21/2025 at prices ranging from $1.32 to $1.35. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the specified range.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:16 UTC GrantOption to purchase Common Stock · Derivative 40,500 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001683811-25-000003 · wk-form4_1740186979.xml · derivative · entry 1

Sacks Natalie · CIK 0001683811 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,500

Underlying: Common Stock · 40,500 shares

Expires 2035-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:20 UTC
Albertson Tina M.Chief Medical Officer
GrantOption to purchase Common Stock · Derivative 66,137 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001917391-25-000003 · wk-form4_1740187228.xml · derivative · entry 2

Albertson Tina M. · CIK 0001917391 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,137

Underlying: Common Stock · 66,137 shares

Expires 2035-02-19

F2 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:20 UTC
Albertson Tina M.Chief Medical Officer
GrantCommon Stock 14,589 $0.00 $0.00
Disclosure

SEC source: 0001917391-25-000003 · wk-form4_1740187228.xml · nonDerivative · entry 1

Albertson Tina M. · CIK 0001917391 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,589

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:17 UTC
Zheng RanDirector
GrantOption to purchase Common Stock · Derivative 40,500 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001885914-25-000003 · wk-form4_1740187054.xml · derivative · entry 1

Zheng Ran · CIK 0001885914 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,500

Underlying: Common Stock · 40,500 shares

Expires 2035-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:21 UTC
Haurwitz Rachel E.Director · President and CEO
GrantOption to purchase Common Stock · Derivative 618,250 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001670579-25-000003 · wk-form4_1740187261.xml · derivative · entry 3

Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 618,250

Underlying: Common Stock · 618,250 shares

Expires 2035-02-19

F3 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:21 UTC
Haurwitz Rachel E.Director · President and CEO
GrantCommon Stock 136,750 $0.00 $0.00
Disclosure

SEC source: 0001670579-25-000003 · wk-form4_1740187261.xml · nonDerivative · entry 1

Haurwitz Rachel E. · CIK 0001670579 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 295,450

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:13 UTC GrantOption to purchase Common Stock · Derivative 40,500 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001643875-25-000003 · wk-form4_1740186801.xml · derivative · entry 1

Braunstein Scott · CIK 0001643875 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,500

Underlying: Common Stock · 40,500 shares

Expires 2035-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:19 UTC
MCCLUNG BARBARA GChief Legal Officer
GrantOption to purchase Common Stock · Derivative 170,000 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001231321-25-000003 · wk-form4_1740187189.xml · derivative · entry 3

MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-02-19

F4 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 20, 2025 Filed Feb 21, 2025 20:19 UTC
MCCLUNG BARBARA GChief Legal Officer
GrantCommon Stock 37,500 $0.00 $0.00
Disclosure

SEC source: 0001231321-25-000003 · wk-form4_1740187189.xml · nonDerivative · entry 1

MCCLUNG BARBARA G · CIK 0001231321 · Chief Legal Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 447,066

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:14 UTC GrantOption to purchase Common Stock · Derivative 40,500 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001230724-25-000003 · wk-form4_1740186837.xml · derivative · entry 1

GUGGENHIME ANDREW · CIK 0001230724 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,500

Underlying: Common Stock · 40,500 shares

Expires 2035-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:18 UTC
Kelly Timothy PChief Technology Officer
GrantOption to purchase Common Stock · Derivative 170,000 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001754067-25-000003 · wk-form4_1740187125.xml · derivative · entry 2

Kelly Timothy P · CIK 0001754067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-02-19

F2 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:18 UTC
Kelly Timothy PChief Technology Officer
GrantCommon Stock 37,500 $0.00 $0.00
Disclosure

SEC source: 0001754067-25-000003 · wk-form4_1740187125.xml · nonDerivative · entry 1

Kelly Timothy P · CIK 0001754067 · Chief Technology Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,500

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:19 UTC
Khan Ruhi AhmadChief Business Officer
GrantOption to purchase Common Stock · Derivative 170,000 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001891113-25-000003 · wk-form4_1740187160.xml · derivative · entry 3

Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-02-19

F4 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:19 UTC
Khan Ruhi AhmadChief Business Officer
GrantCommon Stock 37,500 $0.00 $0.00
Disclosure

SEC source: 0001891113-25-000003 · wk-form4_1740187160.xml · nonDerivative · entry 1

Khan Ruhi Ahmad · CIK 0001891113 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,500

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:18 UTC
Kanner StevenChief Scientific Officer
GrantOption to purchase Common Stock · Derivative 170,000 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001871131-25-000003 · wk-form4_1740187088.xml · derivative · entry 3

Kanner Steven · CIK 0001871131 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,000

Underlying: Common Stock · 170,000 shares

Expires 2035-02-19

F5 · derivative.exercise_date: 25% of the options will vest upon the one-year anniversary of the grant date, February 20, 2026, and 1/48th will vest monthly thereafter over the 36-month period following the one-year cliff, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:18 UTC
Kanner StevenChief Scientific Officer
GrantCommon Stock 37,500 $0.00 $0.00
Disclosure

SEC source: 0001871131-25-000003 · wk-form4_1740187088.xml · nonDerivative · entry 1

Kanner Steven · CIK 0001871131 · Chief Scientific Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 435,120

F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on February 20, 2026, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date.

F2 · balance_after: Includes 10,583 shares purchased pursuant to the Issuer's 2021 Employee Stock Purchase Plan on February 15, 2025.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:17 UTC GrantOption to purchase Common Stock · Derivative 40,500 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001880609-25-000003 · wk-form4_1740187018.xml · derivative · entry 1

Whiting Nancy · CIK 0001880609 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,500

Underlying: Common Stock · 40,500 shares

Expires 2035-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:15 UTC GrantOption to purchase Common Stock · Derivative 40,500 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001893193-25-000004 · wk-form4_1740186934.xml · derivative · entry 1

Richardson-Heron Dara · CIK 0001893193 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,500

Underlying: Common Stock · 40,500 shares

Expires 2035-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
February 20, 2025 Filed Feb 22, 2025 01:14 UTC GrantOption to purchase Common Stock · Derivative 40,500 $0.00 Strike: $1.41 $0.00
Disclosure

SEC source: 0001733883-25-000003 · wk-form4_1740186872.xml · derivative · entry 1

JOHNSON DAVID LEE · CIK 0001733883 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,500

Underlying: Common Stock · 40,500 shares

Expires 2035-02-19

F1 · derivative.exercise_date: One-twelfth of the shares subject to this option will vest on each monthly anniversary of the grant date such that the option will be fully vested on February 20, 2026, subject to the reporting person continuing to provide service to the Issuer through each such vesting date.

Read SEC document
January 29, 2025 Filed Jan 30, 2025 21:02 UTC
Ryali SriramChief Financial Officer
PurchaseCommon Stock 17,360 $1.42 $24,651.20
Disclosure

SEC source: 0001762893-25-000009 · wk-form4_1738270924.xml · nonDerivative · entry 1

Ryali Sriram · CIK 0001762893 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,360

Read SEC document
January 10, 2025 Filed Jan 10, 2025 22:06 UTC
Ryali SriramChief Financial Officer
GrantOption to purchase Common Stock · Derivative 300,000 $0.00 Strike: $1.64 $0.00
Disclosure

SEC source: 0001762893-25-000006 · wk-form4_1736546757.xml · derivative · entry 1

Ryali Sriram · CIK 0001762893 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 300,000

Underlying: Common Stock · 300,000 shares

Expires 2035-01-09

F1 · derivative.exercise_date: 25% of the shares subject to the option shall vest on January 2, 2026, and the remaining shares subject to the option shall vest monthly thereafter (1/48 of the shares per month for the 36 months following January 2, 2026), subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.

Read SEC document
November 20, 2024 Filed Nov 22, 2024 21:01 UTC
Fischesser RyanVP of Finance and Controller
GrantCommon Stock 25,000 $0.00 $0.00
Disclosure

SEC source: 0001871155-24-000005 · wk-form4_1732309285.xml · nonDerivative · entry 1

Fischesser Ryan · CIK 0001871155 · VP of Finance and Controller

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 118,854

F1 · shares: This reflects restricted stock units ("RSUs") that will vest in full on November 20, 2025, subject to the reporting person's continued services to the Issuer through the vesting date. The RSUs will be settled in stock within 30 days after each vesting date.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.